StockNews.AI
MRNA
StockNews.AI
186 days

Moderna Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Updates

1. Moderna reports $1.1 billion net loss and $1.0 billion revenue this quarter. 2. Submitted three mRNA products for regulatory approval, including COVID and RSV vaccines.

2m saved
Insight
Article

FAQ

Why Bearish?

The significant net loss reflects ongoing financial challenges for Moderna. Similar past earnings reports led to stock declines due to investor concerns over profitability.

How important is it?

Earnings significantly influence stock prices and Moderna's submission for regulatory approvals shows potential future revenue streams.

Why Short Term?

Immediate financial results can affect stock price in the short-term. Stakeholders may react quickly to losses or unexpected revenue guidance.

Related Companies

PFENVAXBNTX
Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing Reports full-year revenues of $3.2 billion, GAAP net loss of $(3.6) billion and GAAP diluted EPS of $(9.28) Expects 2025 revenue range of $1.5 to 2.5 billion andending cash balance of approximately $6 billion Submitted three investigational mRNA products for regulatory approval, including Moderna's next-generation COVID vaccine, RSV vaccine for high-risk adults aged 18 to 59, and flu/COVID combination vaccine CAMBRIDGE, MA / ACCESS Newswire / February 14, 2025 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the fourth quarter and fiscal year 2024. "We have made progress in 2024 across our late-stage pipeline and cost reduction efforts.

Related News